Search results
EHA 2024: Odronextamab shows promise in ELM-2 study for follicular lymphoma
Clinical Trials Arena via Yahoo Finance· 1 day agolymphoma (FL) is a chronic disease that accounts for about 20% of non-Hodgkin's lymphoma (NHL)...
...Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory...
Morningstar· 4 days agoGenentech’s Phase III STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Campaign fuels efforts to find better treatments for blood cancers in children
NBC Dallas Fort Worth· 7 hours agoLeukemia and Lymphoma Society's (LLS) Dare to Dream project hopes to raise money for research of...
EHA 2024: AstraZeneca’s Calquence plus chemoimmunotherapy offers new standard for MCL
Pharmaceutical Technology via Yahoo Finance· 1 day agoMCL is a rare and often severe form of non-Hodgkin lymphoma (NHL) that develops when B lymphocytes...
Roche’s Columvi offers extended survival in Phase III DLBCL trial
Clinical Trials Arena via Yahoo Finance· 2 days agoThe trial compared this regimen against MabThera/Rituxan...efficacy of Columvi plus GemOx regimen...
EHA 2024: Brukinsa/Venclexta for CLL/SLL lacks control arm in SEQUOIA trial
Clinical Trials Arena via Yahoo Finance· 1 day agoThe median follow-up for the SEQUOIA trial...17p) and/or TP53 mutation were enrolled. The trial...
Atezolizumab Consolidation Impresses in High-Risk DLBCL
MedPage Today· 5 days agoPostchemotherapy consolidation with atezolizumab (Tecentriq) led to a surprisingly high 2-year...
Roche (RHHBY) Reports Upbeat Data on Columvi From STARGLO Study
Zacks via Yahoo Finance· 1 day agoRoche's (RHHBY) Columvi significantly extends survival in patients with relapsed or refractory...
MD Anderson Research Highlights: EHA 2024 Special | Newswise
Newswise· 6 days agoThe University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research, and prevention. Thes
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 6 days agoPfizer also recently said its new drug, Adcetris, improved overall survival, progression-free ...